Satellos Bioscience (MSLE) Consolidated Net Income (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Consolidated Net Income came in at -$9.7 million in Q1 2026, down 261.3% year-on-year from $6.0 million in Q1 2025, and down 261.3% on a QoQ basis from $6.0 million in Q1 2025.
Satellos Bioscience (MSLE) Consolidated Net Income (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Consolidated Net Income data on file, last reported at -$9.7 million in Q1 2026.
- On a quarterly basis, Consolidated Net Income fell 261.3% year-over-year to -$9.7 million in Q1 2026; TTM through Mar 2026 was -$3.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$25.0 million, down 23.54% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$9.7 million, down from $6.0 million in the prior quarter.
- Over the last five years, Consolidated Net Income for MSLE reached as high as $6.0 million in Q1 2025 and fell as low as -$9.7 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Satellos Bioscience | 148.71 Mn | 148.71 Mn | - | -9.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.70 Mn |
| Mar 31, 2025 | 6.02 Mn |